(CLPT) Clearpoint Neuro - Overview
Stock: ClearPoint, Neurosurgery, Navigation, Mri, Catheter
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 83.2% |
| Relative Tail Risk | -17.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.04 |
| Alpha | -54.40 |
| Character TTM | |
|---|---|
| Beta | 1.897 |
| Beta Downside | 2.080 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.18% |
| CAGR/Max DD | 0.24 |
Description: CLPT Clearpoint Neuro December 29, 2025
ClearPoint Neuro, Inc. (NASDAQ: CLPT) is a U.S.–based medical-device firm that designs and markets MRI-guided platforms for minimally invasive brain procedures. Its flagship ClearPoint system integrates navigation, targeting, and delivery tools for deep-brain stimulation (DBS) leads, biopsy needles, laser ablation catheters, and intracerebral drug infusion. The company operates under a network of licensing and research collaborations with Clinical Laserthermia Systems AB, Philips, UCB Biopharma, NE Scientific, UCSF, and Johns Hopkins, and it rebranded from MRI Interventions, Inc. in February 2020.
Key operating metrics (Q3 2024): revenue of $3.1 million, up 42 % YoY, driven by a 30 % increase in system installations; cash and equivalents of $28 million, providing ~18 months of runway at current burn rates; and a pipeline of three FDA-cleared indications (DBS, laser ablation, and convection-enhanced delivery). Sector drivers include the expanding market for image-guided neurosurgery-projected to grow at a CAGR of ~9 % through 2030-and rising reimbursement for MRI-guided procedures under Medicare’s new “Neuro-Imaging Intervention” policy.
For a deeper, data-focused look at how ClearPoint’s valuation compares to peers, you might explore ValueRay’s analytical tools.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -23.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -0.32 > 1.0 |
| NWC/Revenue: 126.1% < 20% (prev 88.00%; Δ 38.06% < -1%) |
| CFO/TA -0.22 > 3% & CFO -13.1m > Net Income -23.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.4m) vs 12m ago 3.03% < -2% |
| Gross Margin: 61.31% > 18% (prev 0.60%; Δ 6071 % > 0.5%) |
| Asset Turnover: 68.29% > 50% (prev 75.71%; Δ -7.42% > 0%) |
| Interest Coverage Ratio: -36.66 > 6 (EBITDA TTM -21.3m / Interest Expense TTM 623.0k) |
Altman Z'' -14.57
| A: 0.72 (Total Current Assets 51.3m - Total Current Liabilities 8.05m) / Total Assets 60.4m |
| B: -3.46 (Retained Earnings -209.1m / Total Assets 60.4m) |
| C: -0.45 (EBIT TTM -22.8m / Avg Total Assets 50.3m) |
| D: -4.69 (Book Value of Equity -208.8m / Total Liabilities 44.5m) |
| Altman-Z'' Score: -14.57 = D |
Beneish M -3.39
| DSRI: 0.91 (Receivables 4.00m/3.88m, Revenue 34.3m/30.4m) |
| GMI: 0.98 (GM 61.31% / 60.38%) |
| AQI: 0.67 (AQ_t 0.02 / AQ_t-1 0.02) |
| SGI: 1.13 (Revenue 34.3m / 30.4m) |
| TATA: -0.17 (NI -23.1m - CFO -13.1m) / TA 60.4m) |
| Beneish M-Score: -3.39 (Cap -4..+1) = AA |
What is the price of CLPT shares?
Over the past week, the price has changed by +4.10%, over one month by -11.85%, over three months by -26.17% and over the past year by -28.78%.
Is CLPT a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CLPT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29 | 115.5% |
| Analysts Target Price | 29 | 115.5% |
| ValueRay Target Price | 13.1 | -3% |
CLPT Fundamental Data Overview February 03, 2026
P/B = 24.2312
Revenue TTM = 34.3m USD
EBIT TTM = -22.8m USD
EBITDA TTM = -21.3m USD
Long Term Debt = 29.2m USD (from longTermDebt, last quarter)
Short Term Debt = 347.0k USD (from shortTermDebt, last quarter)
Debt = 35.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.48m USD (from netDebt column, last quarter)
Enterprise Value = 382.2m USD (384.6m + Debt 35.7m - CCE 38.2m)
Interest Coverage Ratio = -36.66 (Ebit TTM -22.8m / Interest Expense TTM 623.0k)
EV/FCF = -27.65x (Enterprise Value 382.2m / FCF TTM -13.8m)
FCF Yield = -3.62% (FCF TTM -13.8m / Enterprise Value 382.2m)
FCF Margin = -40.27% (FCF TTM -13.8m / Revenue TTM 34.3m)
Net Margin = -67.40% (Net Income TTM -23.1m / Revenue TTM 34.3m)
Gross Margin = 61.31% ((Revenue TTM 34.3m - Cost of Revenue TTM 13.3m) / Revenue TTM)
Gross Margin QoQ = 63.20% (prev 60.29%)
Tobins Q-Ratio = 6.33 (Enterprise Value 382.2m / Total Assets 60.4m)
Interest Expense / Debt = 1.52% (Interest Expense 543.0k / Debt 35.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -18.0m (EBIT -22.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.37 (Total Current Assets 51.3m / Total Current Liabilities 8.05m)
Debt / Equity = 2.25 (Debt 35.7m / totalStockholderEquity, last quarter 15.9m)
Debt / EBITDA = 0.12 (negative EBITDA) (Net Debt -2.48m / EBITDA -21.3m)
Debt / FCF = 0.18 (negative FCF - burning cash) (Net Debt -2.48m / FCF TTM -13.8m)
Total Stockholder Equity = 20.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.03% (Net Income -23.1m / Total Assets 60.4m)
RoE = -114.3% (Net Income TTM -23.1m / Total Stockholder Equity 20.2m)
RoCE = -46.18% (EBIT -22.8m / Capital Employed (Equity 20.2m + L.T.Debt 29.2m))
RoIC = -51.91% (negative operating profit) (NOPAT -18.0m / Invested Capital 34.8m)
WACC = 11.91% (E(384.6m)/V(420.4m) * Re(12.90%) + D(35.7m)/V(420.4m) * Rd(1.52%) * (1-Tc(0.21)))
Discount Rate = 12.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.44%
Fair Price DCF = unknown (Cash Flow -13.8m)
EPS Correlation: 24.34 | EPS CAGR: 23.81% | SUE: 4.0 | # QB: 1
Revenue Correlation: 97.16 | Revenue CAGR: 21.40% | SUE: -1.32 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.23 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.81 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+3.0% | Growth Revenue=+50.0%